Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies, Inc. completed its transition to Streamex Corp. after merging with Streamex Exchange Corporation and changing its Nasdaq ticker to STEX. Company news now centers on Streamex’s real-world-asset and gold tokenization business, including institutional-grade infrastructure for on-chain gold markets, a gold-denominated treasury strategy, and tokenized yield-bearing gold products.
Recurring updates also cover strategic partnerships, exchange-traded product concepts, public offerings, shareholder voting matters, capital-structure disclosures, and the company’s completed rebrand from a medical-device issuer associated with the PURE EP Platform to a gold tokenization and treasury-focused public company.
BioSig Technologies announced FDA approval to proceed with a Phase II clinical trial for its antiviral drug, merimepodib, aimed at treating COVID-19 in hospitalized patients requiring oxygen support. This study will be randomized and placebo-controlled, involving multiple centers including three Mayo Clinic sites. The trial's success could signify a breakthrough in COVID-19 treatment options. The company emphasizes the drug's broad-spectrum activity against COVID-19, positioning it as a potential pivotal solution amid the pandemic.
BioSig Technologies (BSGM) announced positive pre-clinical results for merimepodib in combination with remdesivir, showing a significant reduction of SARS-CoV-2 viral production to undetectable levels. This study, conducted at the Galveston National Laboratory, underscores the potential of merimepodib as both a standalone treatment and in synergy with remdesivir. The first clinical trial is planned for hospitalized patients requiring supplemental oxygen, evaluating the drug's effectiveness. The results aim to pave the way for a phase 2 study upon FDA clearance.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced the appointment of Mr. Michael Schmertzler to the Board of Directors of its subsidiary, ViralClear Pharmaceuticals, Inc. Schmertzler brings extensive experience in biotechnology, including his role as Chairman of PTC Therapeutics since 2004. He has been pivotal in various biotech ventures and possesses a strong financial background with investment banks. ViralClear focuses on developing merimepodib, an anti-viral candidate targeting RNA viruses, which has shown significant potential against COVID-19 in preliminary studies.
BioSig Technologies, Inc. (NASDAQ: BSGM) has appointed Mr. Dennis Purcell to the Board of Directors of its subsidiary ViralClear Pharmaceuticals. Purcell is a seasoned life sciences investor, founder of Aisling Capital, and former Managing Director at Chase H&Q, involved in over $10 billion of financing transactions. ViralClear is developing merimepodib, an antiviral candidate showing promise against COVID-19. Mayo Clinic will be a site for a Phase II trial, with results expected within three months. The company aims to leverage Purcell's expertise as it advances its clinical programs.
Summary not available.
Summary not available.